Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q4 2020 (← Previous) (Next →)

Filing Date: Feb 16, 2021

Total Value ($000): $666,876 (100.0% shares, 0.0% debt)

Holdings (19)

REPL Replimune Group 29.0%

Value ($000) $193,603 Shares 5,074,783 Est. Cost $17.40 Unrealized +139.5%

— Kronos Bio 17.1%

Value ($000) $114,052 Shares 3,818,283 Est. Cost $29.87 Unrealized —

— Morphic Holding 14.7%

Value ($000) $98,025 Shares 2,921,771 Est. Cost $19.82 Unrealized —

— Spruce Biosciences 7.9%

Value ($000) $52,534 Shares 2,161,022 Est. Cost $24.31 Unrealized —

AVIR Atea Pharmaceuticals 5.3%

Value ($000) $35,396 Shares 847,208 Est. Cost $32.23 Unrealized 0.0%

GOSS Gossamer Bio 4.8%

Value ($000) $32,110 Shares 3,320,608 Est. Cost $20.85 Unrealized -52.8%

IMUX Immunic 4.1%

Value ($000) $27,341 Shares 1,788,160 Est. Cost $13.89 Unrealized +29.3%

— Checkmate Pharmaceuticals 2.9%

Value ($000) $19,478 Shares 1,335,050 Est. Cost $11.51 Unrealized —

ARQT Arcutis Biothereapeutics 2.7%

Value ($000) $18,009 Shares 640,199 Est. Cost $26.87 Unrealized -8.8%

— Syros Pharmaceuticals 2.5%

Value ($000) $16,953 Shares 1,562,500 Est. Cost $10.85 Unrealized —

— Paratek Pharmaceuticals 2.4%

Value ($000) $16,279 Shares 2,600,410 Est. Cost $34.18 Unrealized —

— Alpine Immune Sciences 2.4%

Value ($000) $16,190 Shares 1,284,900 Est. Cost $8.79 Unrealized —

— ESSA Pharma 1.3%

Value ($000) $8,419 Shares 705,693 Est. Cost $3.14 Unrealized —

— FibroGen 0.7%

Value ($000) $4,846 Shares 130,646 Est. Cost $27.34 Unrealized —

— Cidara Therapeutics 0.6%

Value ($000) $4,010 Shares 2,005,249 Est. Cost $5.64 Unrealized —

TRVI Trevi Therapeutics 0.5%

Value ($000) $3,330 Shares 1,263,408 Est. Cost $8.20 Unrealized -60.5%

— Jounce Therapeutics 0.4%

Value ($000) $2,345 Shares 334,965 Est. Cost $21.99 Unrealized —

— ObsEva 0.3%

Value ($000) $2,079 Shares 999,364 Est. Cost $9.76 Unrealized —

— Pieris Pharmaceuticals 0.3%

Value ($000) $1,877 Shares 750,741 Est. Cost $1.83 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
REPL	Replimune Group	5,074,783	$193,603	29.0%	$17.40	+139.5%	Common Stock	76029N106
—	Kronos Bio	3,818,283	$114,052	17.1%	$29.87	—	Common Stock	50107A104
—	Morphic Holding	2,921,771	$98,025	14.7%	$19.82	—	Common Stock	61775R105
—	Spruce Biosciences	2,161,022	$52,534	7.9%	$24.31	—	Common Stock	85209E109
AVIR	Atea Pharmaceuticals	847,208	$35,396	5.3%	$32.23	0.0%	Common Stock	04683R106
GOSS	Gossamer Bio	3,320,608	$32,110	4.8%	$20.85	-52.8%	Common Stock	38341P102
IMUX	Immunic	1,788,160	$27,341	4.1%	$13.89	+29.3%	Common Stock	4525EP101
—	Checkmate Pharmaceuticals	1,335,050	$19,478	2.9%	$11.51	—	Common Stock	162818108
ARQT	Arcutis Biothereapeutics	640,199	$18,009	2.7%	$26.87	-8.8%	Common Stock	03969K108
—	Syros Pharmaceuticals	1,562,500	$16,953	2.5%	$10.85	—	Common Stock	87184Q107
—	Paratek Pharmaceuticals	2,600,410	$16,279	2.4%	$34.18	—	Common Stock	699374302
—	Alpine Immune Sciences	1,284,900	$16,190	2.4%	$8.79	—	Common Stock	02083G100
—	ESSA Pharma	705,693	$8,419	1.3%	$3.14	—	Common Stock	29668H708
—	FibroGen	130,646	$4,846	0.7%	$27.34	—	Common Stock	31572Q808
—	Cidara Therapeutics	2,005,249	$4,010	0.6%	$5.64	—	Common Stock	171757107
TRVI	Trevi Therapeutics	1,263,408	$3,330	0.5%	$8.20	-60.5%	Common Stock	89532M101
—	Jounce Therapeutics	334,965	$2,345	0.4%	$21.99	—	Common Stock	481116101
—	ObsEva	999,364	$2,079	0.3%	$9.76	—	Common Stock	H5861P103
—	Pieris Pharmaceuticals	750,741	$1,877	0.3%	$1.83	—	Common Stock	720795103